Dr. Sarah Chen
June 14, 2026
Retatrutide (LY3437943) represents a novel pharmacological approach to comorbid obesity and degenerative joint disease. As a first-in-class once-weekly injectable agent, retatrutide simultaneously activates glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon receptors—a triple hormone receptor agonist mechanism distinct from dual GLP-1/GIP agents now established in clinical practice.
The rationale for evaluating retatrutide in knee osteoarthritis (OA) stems from the well-characterized relationship between adiposity and joint degeneration. Excess body weight increases mechanical loading on weight-bearing joints while promoting systemic inflammation through adipose tissue-derived cytokines. Whether weight reduction alone drives pain improvement or whether retatrutide's pleiotropic metabolic effects directly modulate osteoarthritic pathology remains an open mechanistic question addressed partially by the TRIUMPH-4 trial design.
The TRIUMPH-4 trial (NCT05931367) was a 68-week, randomized, double-blind, placebo-controlled Phase 3 study conducted across multiple global sites [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05931367). The trial enrolled 445 adults with obesity or overweight status and radiologically confirmed knee osteoarthritis, stratified into three parallel arms:
Key inclusion criteria required participants to meet both clinical and radiological American College of Rheumatology (ACR) criteria for knee OA, with moderate radiographic changes (Kellgren-Lawrence Grade 2 or 3). Baseline characteristics reflected a population with substantial disease burden: mean body weight 112.7 kg, mean BMI 40.4 kg/m², and 84% of participants presenting with BMI ≥35 kg/m². Index knee pain duration exceeded 12 weeks prior to screening, with pain present on >15 days during the preceding month.
Critically, the trial excluded individuals with type 2 diabetes mellitus, isolating the effects of retatrutide in a non-diabetic obese population with OA—a population for which limited pharmacological interventions exist beyond nonsteroidal anti-inflammatory drugs (NSAIDs) and intra-articular corticosteroid injections.
Participants initiated retatrutide at 2 mg once-weekly with stepwise dose escalation every four weeks (2→4→6→9 mg for the 9 mg group; 2→4→6→9→12 mg for the 12 mg group) to mitigate gastrointestinal tolerability concerns.
The TRIUMPH-4 trial employed two co-primary endpoints:
Weight Loss Outcomes (efficacy estimand):
Using the treatment-regimen estimand (reflecting real-world adherence patterns), weight loss was attenuated but remained clinically significant: 20% at 9 mg and 23.7% at 12 mg versus 4.6% in placebo.
Moreover, 51% of participants in the 12 mg retatrutide group achieved ≥25% body weight reduction—a threshold associated with improved metabolic and musculoskeletal outcomes in obesity literature.
Knee Pain Outcomes (WOMAC pain subscale):
This translated to a 75.8% average pain reduction in the retatrutide arms. Clinically meaningful pain response (≥70% WOMAC pain reduction) was achieved by:
A post-hoc analysis revealed complete pain resolution (zero pain score) at week 68 in 14.1% of 9 mg recipients and 12% of 12 mg recipients, compared to 4.2% in placebo—suggesting a subset may experience disease remission rather than mere symptom suppression.
Beyond pain, retatrutide improved WOMAC physical function subscale scores:
This improvement in functional capacity may reflect both pain reduction and direct weight-bearing benefits from substantial weight loss.
Secondary metabolic endpoints demonstrated systemic anti-inflammatory and cardiometabolic benefits:
These secondary outcomes align with the hypothesis that retatrutide's pleiotropic effects on metabolic inflammation may contribute to joint pain improvement independently of mechanical load reduction.
The trial design does not definitively isolate whether pain reduction results from weight loss alone or reflects direct anti-inflammatory or joint-protective effects of GIP/GLP-1/glucagon receptor activation. However, several observations warrant consideration:
While the TRIUMPH-4 announcement emphasized efficacy, detailed safety data have not yet been published in peer-reviewed form. Regulatory submissions and ongoing Phase 3 trials (seven additional readouts expected in 2026) will clarify the adverse event profile in this non-diabetic OA population. GLP-1 receptor agonists are known to carry gastrointestinal tolerability risks (nausea, vomiting, diarrhea), particularly during dose escalation—a consideration reflected in the stepwise titration protocol employed.
The TRIUMPH-4 results represent the first Phase 3 evidence that a triple receptor agonist can provide clinically meaningful benefit in knee OA comorbid with obesity. If regulatory approval is granted, retatrutide may expand the therapeutic armamentarium for patients who are inadequately responsive to NSAIDs or intra-articular injections and who lack access to bariatric surgery.
For researchers, these data raise mechanistic questions: Do GIP, GLP-1, or glucagon receptor activation directly modulate synovial inflammation or chondrocyte biology? Does the magnitude of weight loss threshold necessary for pain improvement differ between single and triple agonists? Future translational work examining synovial fluid biomarkers, cartilage imaging, and receptor expression in OA tissue may illuminate these pathways.
Several limitations merit acknowledgment. The trial excluded diabetic individuals, limiting generalizability to the substantial population with concurrent type 2 diabetes and OA. The 68-week observation window does not address long-term durability of pain benefit or cartilage preservation. Radiographic progression was not a primary endpoint, so whether retatrutide slows structural OA advancement remains unknown. Finally, the trial did not include an active comparator (e.g., intensive weight loss counseling or established OA pharmacotherapy), limiting assessment of relative clinical benefit.
The TRIUMPH-4 Phase 3 trial demonstrates that retatrutide achieves substantial, clinically meaningful reductions in knee osteoarthritis pain (75.8%) concurrent with significant body weight loss (28.7%) in adults with obesity. The magnitude of pain improvement and the proportion achieving complete pain resolution suggest mechanisms beyond mechanical load reduction, though definitive evidence of direct joint-protective effects awaits further mechanistic investigation. With seven additional Phase 3 readouts anticipated in 2026, retatrutide's role in treating obesity-related comorbidities—including knee OA, sleep apnea, and chronic back pain—will become clearer. Researchers investigating metabolic inflammation, GLP-1 biology, and OA pathophysiology should monitor regulatory submissions and subsequent publications for insights into the triple agonist mechanism in degenerative joint disease.